这次讨论围绕 Exor 这家意大利控股公司展开，主持人此前曾推荐它作为以大幅折扣投资法拉利（Ferrari）的方式。2026年初，Exor 的股价较其净资产价值（NAV）折价高达50-60%，这实际上让投资者能以比直接购买便宜得多的价格拥有法拉利股票。 然而，此后 Exor 的股价下跌，NAV 折扣也随之扩大。市场担忧的一个关键原因在于 Exor 决定出售价值30亿欧元的法拉利股份。尽管考虑到法拉利是 Exor 的“皇冠上的明珠”，也是许多投资者选择 Exor 的主要原因，此举颇具争议，但出售时法拉利的市盈率正处于高位，事后看来，这表明时机把握得相当精明。所得资金旨在用于新的收购。然而，市场要么将此解读为 Exor 示弱的信号，要么认为其对 Exor 的再投资能力缺乏信任，导致折价幅度扩大。主持人承认，这种折价收窄的时机很难把握，像 Exor 这样的控股公司通常会长期低于 NAV 交易，不像伯克希尔哈撒韦（Berkshire Hathaway）等少数例外。 尽管 Exor 的股价表现不佳，法拉利本身却持续表现出色，创下季度业绩纪录，并预计将创下史上最佳年度业绩。然而，其股价也经历了一番波动，市盈率从57倍的峰值跌至约30倍。这种重新估值部分归因于法拉利增长速度“趋于成熟”的看法，以及其新电动车型 Ferrari Luce（路西）市场反响不一。 Luce 作为法拉利的首款纯电动汽车，最初发布时导致公司股价下跌7-8%。批评者，包括法拉利前首席执行官，质疑其是否符合品牌形象，理由是电动汽车更注重实用性而非极致性能，以及由于大型电池导致的妥协性设计。然而，主持人认为 Luce 旨在将法拉利的客户群扩展到硅谷和中国等市场中“对技术更前卫的群体”。事实上，Luce 在中国一个月内便售罄，订单已排到2027年末，这表明市场需求强劲。法拉利随后将2030年电动车型的预期比例从40%下调至20%，表明采取了更为谨慎的态度。 2026年推出的其他法拉利新车型包括 Testarossa Spider（一款拥有超过1000马力的混合动力车）和 Amulfi Spider（一款定位为“入门级”的敞篷车，售价低于30万美元，而法拉利平均售价为45万美元）。主持人指出，法拉利通过控制产量提升来维持稀缺性，并专注于高利润的定制化和增值服务。 分析法拉利的关键绩效指标（KPIs），主持人发现： * **销量增长：** 预计每年增长1-2%。尽管2026年第一季度的数据可能略有收缩，但考虑到品牌注重定价权，这不是主要担忧。 * **营收增长：** 预计增长7%（其中5%来自定价，1-2%来自销量）。法拉利的定价权显而易见，每单位平均收入显著增加，展示了“奢侈品的魅力”。 * **研发费用占销售额的比例：** 保持在13%的良好水平。 * **运营利润率：** 持续扩大，已接近30%的目标。 法拉利的商业模式极具韧性，依赖于稀缺性和忠实的客户群（85%是重复购买者）。宏观经济风险，如年轻一代驾车减少或关税，对法拉利超富裕客户群体的影响微乎其微，他们对价格极不敏感，并接受高昂的维护成本。其一级方程式车队是强大的营销工具，即使近期没有夺冠，也巩固了其品牌传奇地位。 除了法拉利，Exor 的投资组合还包括 Stellantis（2026年下跌48%）、CNH（上涨11%）和 Philips（上涨2%）。Exor 还积极剥离非核心资产，产生了20亿欧元的收益并精简了其持股，这可能预示着将转向更专注的战略。 Exor 的一个显著积极进展是其资产管理部门 Lingotto。Lingotto 的管理资产规模（AUM）自2023年以来增长了两倍，超过100亿美元，主要得益于强劲的投资回报而非资金流入。其成功部分归因于对 Carvana 和 Teva Pharmaceuticals 等公司的集中押注，这些公司实现了巨额收益。Lingotto 不断增长的 AUM 预示着 Exor 未来通过管理费和业绩费获得持续性收入。 主持人总结说，他们对 Exor 的原始投资论点基本保持不变。法拉利的内在价值假设依然成立，而大幅的 NAV 折扣仍使 Exor 成为一个有吸引力的、具有不对称回报潜力的投资。尽管折价可能持续存在，但其背后有价值的资产以及法拉利复利增长的潜力，最终会提振 Exor 的股价，这使得其具有强大的吸引力。该论点的失效条件将包括 Exor 持续做出糟糕的资本配置决策（例如，溢价收购平庸资产而非回购股票），或者领导层出现重大不稳定，例如 Exor 首席执行官兼法拉利董事长约翰·埃尔坎（John Elkann）失去控制权。这项投资需要耐心，寄希望于 Exor 的市场价格最终能与其不断增长的 NAV 趋同。

The discussion centers on Exor, an Italian holding company, which the hosts previously recommended as a way to invest in Ferrari at a significant discount. At the beginning of 2026, Exor offered a 50-60% discount to its Net Asset Value (NAV), effectively allowing investors to own Ferrari shares at a much cheaper price than buying them directly. However, since then, Exor's stock has declined, and the NAV discount has widened. A key reason for market concern was Exor's decision to sell off €3 billion worth of its Ferrari stake. While this move was controversial given Ferrari is Exor's "crown jewel" and a primary reason many invested in Exor, it was done when Ferrari was trading at high P/E multiples, suggesting astute timing in hindsight. The proceeds were intended for new acquisitions. The market, however, viewed this either as a sign of weakness or a lack of trust in Exor's ability to reinvest well, leading to a widened discount. The hosts acknowledge that timing the closing of such a discount is difficult, and holding companies like Exor often trade below NAV for extended periods, unlike rare exceptions like Berkshire Hathaway. Despite Exor's stock performance, Ferrari itself has continued to excel, posting record quarters and guiding for its best year ever. However, its stock experienced volatility, falling from a peak P/E of 57x to around 30x earnings. This re-rating was partly attributed to the perceived "maturing" of Ferrari's growth rate and the mixed reception of its new electric vehicle, the Ferrari Luce. The Luce, Ferrari's first fully electric car, initially caused the stock to drop 7-8%. Critics, including Ferrari's former CEO, questioned its alignment with the brand's identity, citing EVs' focus on practicality over extreme performance and the design compromises due to large batteries. However, the hosts argue the Luce aims to expand Ferrari's customer base to a more "tech-forward cohort" in markets like Silicon Valley and China. Indeed, the Luce sold out in China within a month, and its order book extends to late 2027, indicating strong demand. Ferrari has since revised down its expectation for EV models by 2030 from 40% to 20%, suggesting a more cautious approach. Other new Ferrari models introduced in 2026 include the Testarossa Spider (a hybrid with over 1000 hp) and the Amulfi Spider (a convertible positioned as a more "entry-level" model at under $300,000, compared to the average Ferrari price of $450,000). The hosts note Ferrari's strategy of maintaining scarcity through managed production ramp-ups and focusing on high-margin customization and services. Analyzing Ferrari's key performance indicators (KPIs), the hosts found: * **Volume Growth:** Expected 1-2% annually, though 2026 Q1 numbers suggest potential slight contraction, it's not a major concern given the brand's focus on pricing. * **Revenue Growth:** Expected 7% (5% from pricing, 1-2% from volume). Ferrari's pricing power is evident, with average revenue per unit significantly increasing, demonstrating the "beauty of luxury." * **R&D as % of Sales:** Tracking well at 13%. * **Operating Margins:** Expanding, nearly reaching the 30% target. Ferrari's business model is remarkably resilient, relying on scarcity and a dedicated customer base (85% repeat buyers). Macroeconomic risks like younger generations driving less or tariffs have minimal impact on Ferrari's ultra-wealthy clientele, who exhibit significant price insensitivity and accept high maintenance costs. Its Formula 1 team serves as a powerful marketing tool, reinforcing its legacy even without recent championships. Beyond Ferrari, Exor's portfolio includes Stellantis (down 48% in 2026), CNH (up 11%), and Philips (up 2%). Exor has also actively divested non-core assets, generating €2 billion and streamlining its holdings, which could signal a move towards a more focused strategy. A notable positive development for Exor is Lingotto, its asset management division. Lingotto's Assets Under Management (AUM) have tripled to over $10 billion since 2023, primarily driven by strong investment returns rather than capital inflows. Its success is partly attributed to concentrated bets on companies like Carvana and Teva Pharmaceuticals, which saw massive gains. Lingotto's growing AUM promises future recurring revenue for Exor through management and performance fees. The hosts conclude that their original thesis for Exor remains largely intact. Ferrari's intrinsic value assumptions are holding, and the wide discount to NAV still makes Exor an attractive, asymmetric bet. While discounts can persist, the presence of valuable underlying assets and the potential for Ferrari's compounding growth to eventually lift Exor's stock makes it compelling. Kill criteria for the thesis would include Exor making consistently poor capital allocation decisions (e.g., overpaying for mediocre assets instead of buybacks) or significant instability in the leadership, such as John Elkann (Exor's CEO and chairman of Ferrari) losing control. The investment requires patience, banking on the eventual convergence of Exor's market price with its growing NAV.